Several in vivo and in vitro studies suggest that PKCα inhibitors may be of potential therapeutic value against human pancreatic cancers [241,242,243,244]; however, there are no reports of clinical trials using PKCα inhibitors. This evidence concerns the gene PRKCA and familial pancreatic carcinoma.